AnaptysBio, Inc.
Antibodies Directed Against Programmed Death-1(PD-1)

Last updated:

Abstract:

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.

Status:
Application
Type:

Utility

Filling date:

13 Jul 2020

Issue date:

3 Jun 2021